Categories: Technology

Singapore eDevelopment (SGX:40V) Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson’s Research at Neuroscience 2018

Singapore, November 24, 2018: Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“SeD”), through its subsidiary, Global BioLife Inc. (“Global BioLife”) is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California.

SeD said the presentation titled, “Myricetin derivatives ameliorate deficits in 6-OHDA animal model of Parkinson’s disease,” will detail the results of an Integrated Drug Discovery program at Charles River Discovery Service covering Pharmacokinetics, Maximum Toxicity Dose, and an in vivo animal model of Parkinson’s Disease. In essence the drug has been designed to work better than current treatments and has performed as well or better in animal models.

“More than 10 million people around the world have Parkinson’s Disease,” said Dr. Roscoe M. Moore, Jr., former Senior Assistant Surgeon General of the United States and Global BioLife’s Chief Scientific Advisor. He also commented that “the team’s unique approach to drug development is key to this success.”

“We are extremely pleased and hopeful with the initial results of Linebacker and what the data shows for the potential treatment of central nervous system (“CNS”) diseases. Linebacker is a direct response to the global need for effective and affordable cures,” said Dr. Peihong Tang, Global BioLife’s Director and Chief Executive Officer.

“We’re excited to have received validating laboratory data of our Linebacker pharmaceuticals,” said Mr. Daryl Thompson, Global BioLife’s Director of Scientific Initiatives and inventor of the compounds. “This data proves our unique approach to CNS diseases could be a much-needed solution and could ease widespread suffering globally.”

With almost 36,000 members, the Society for Neuroscience is the world’s largest organisation of scientists and physicians devoted to understanding the brain and the nervous system. Selection for inclusion in this prestigious event is indicative of the compelling results generated by this research.

The abstract for this presentation can be accessed here: https://bit.ly/2yYbA79

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

8 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago